HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reverse transcriptase inhibitors promote the remodelling of nuclear architecture and induce autophagy in prostate cancer cells.

Abstract
Emerging data indicate that the reverse transcriptase (RT) protein encoded by LINE-1 transposable elements is a promising cancer target. Nonnucleoside RT inhibitors, e.g. efavirenz (EFV) and SPV122.2, reduce proliferation and promote differentiation of cancer cells, concomitant with a global reprogramming of the transcription profile. Both inhibitors have therapeutic anticancer efficacy in animal models. Here we have sought to clarify the mechanisms of RT inhibitors in cancer cells. We report that exposure of PC3 metastatic prostate carcinoma cells to both RT inhibitors results in decreased proliferation, and concomitantly induces genome damage. This is associated with rearrangements of the nuclear architecture, particularly at peripheral chromatin, disruption of the nuclear lamina, and budding of micronuclei. These changes are reversible upon discontinuation of the RT-inhibitory treatment, with reconsititution of the lamina and resumption of the cancer cell original features. The use of pharmacological autophagy inhibitors proves that autophagy is largely responsible for the antiproliferative effect of RT inhibitors. These alterations are not induced in non-cancer cell lines exposed to RT inhibitors. These data provide novel insight in the molecular pathways targeted by RT inhibitors in cancer cells.
AuthorsCristina Bellisai, Ilaria Sciamanna, Paola Rovella, Daniela Giovannini, Mirko Baranzini, Giusj Monia Pugliese, Mohammad Salik Zeya Ansari, Ciro Milite, Paola Sinibaldi-Vallebona, Roberto Cirilli, Gianluca Sbardella, Pietro Pichierri, Daniela Trisciuoglio, Patrizia Lavia, Annalucia Serafino, Corrado Spadafora
JournalCancer letters (Cancer Lett) Vol. 478 Pg. 133-145 (05 28 2020) ISSN: 1872-7980 [Electronic] Ireland
PMID32112906 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2020 Elsevier B.V. All rights reserved.
Chemical References
  • 2-(sec-butylthio)-6-(1-(2,6-difluorophenyl)propyl)-5-methylpyrimidin-4(3H)-one
  • Alkynes
  • Benzoxazines
  • Cyclopropanes
  • Pyrimidinones
  • Reverse Transcriptase Inhibitors
  • efavirenz
Topics
  • Alkynes (pharmacology)
  • Autophagy
  • Benzoxazines (pharmacology)
  • Cell Differentiation
  • Cell Line, Tumor
  • Cell Nucleus (drug effects, genetics)
  • Cell Proliferation (drug effects)
  • Cyclopropanes (pharmacology)
  • DNA Damage
  • Humans
  • Male
  • PC-3 Cells
  • Prostatic Neoplasms (drug therapy, genetics, metabolism)
  • Pyrimidinones (pharmacology)
  • Reverse Transcriptase Inhibitors (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: